The new KCE health economics guidelines 2025: how to deal with uncertainties

Join us for an exclusive event dedicated to exploring the upcoming KCE Health Economics (HE) Guidelines for 2025. Discover how these guidelines address key uncertainties and their implications for healthcare decision-making at national and international levels.

Who have registered too?

47 Attendees (including 8 not visible)
Last name First name Organization
Abdallah Khadidja BAYER sa-nv
Bily Caroline GlaxoSmithKline Pharmaceuticals sa/nv
Block Sebastien Alexion Pharmaceuticals
Borgers Annelies Janssen-Cilag NV
Boydens Lukas S.A. NOVO NORDISK PHARMA N.V.
Braspenning Tinne ISMS
Broeckhoven - PhaBio Support Katleen CareForce One
Cattoir Céline Healixia
Coppens Katrien KS Pharma
D'haene Barbara LIVV - Two Point Zero Consultancy BV
Darquennes Eline MSD Europe Belgium SRL
De Cock Roosmarijn Axes Health BV
De Langhe Sofie Innosens bv
De Smet Pascale Insmed Netherlands BV
Dewilde Sarah SHE BV
Ghasemi Nilofar MENARINI BENELUX NV
Heirman Margino B. Braun Medical NV
Hendrickx Els What ELS matters c.v.
Khaouiry Asmae Axes Health BV
Martens Arne E&A Consultants
Mergan Stephanie HEBIAS bv
Minnaert An-Katrien Axes Health BV
Poirrier Jean-Etienne -
Present Erik Kintiga (AxTalis BV)
Rombaut Toon Almirall N.V.
Theys Kristof Kintiga (AxTalis BV)
Tops Sven Kintiga (AxTalis BV)
Tsakeu Elyonore AbbVie S.A/N.V
Van Den Daele Bart GILEAD Sciences Belgium bv
van Dijck Patricia pharma.be VZW
Van Hoorenbeeck Sandra Janssen-Cilag NV
Vandebrouck Tom Vandebrouck Coaching and consulting
Vandendriessche Frank Ficaja Farma
Vanderdonck Frank Kintiga (AxTalis BV)
Vandersmissen Ine Janssen-Cilag NV
Verheecke Annouk Kintiga (AxTalis BV)
Wambacq Liske Nuwhï
Willaert Marjan pharma.be VZW
Wollaert Lieve LIWOMA BV

Attendees at The new KCE health economics guidelines 2025: how to deal with uncertainties